Skip to content

A Comparative Study on the Efficacy of High-Frequency and Theta-Burst Stimulation rTMS in Improving Cognitive Function in Schizophrenia, and a Mechanistic Investigation of Serum IGF-2

A Comparative Study on the Efficacy of High-Frequency and Theta-Burst Stimulation rTMS in Improving Cognitive Function in Schizophrenia, and a Mechanistic Investigation of Serum IGF-2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117979
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

cTBS + real stimulation:cTBS + real stimulation
Sham stimulation control group:Sham stimulation control (using the same coil with a shielding device to simulate sounds and sensations)
High-frequency rTMS (10Hz) + real stimulation:High-frequency rTMS (10Hz) + real stimulation
iTBS + real stimulation:iTBS + real stimulation

Sponsors

Jiangxi Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Meet the DSM-5 diagnostic criteria for schizophrenia; 2.aged 18-55 years; 3.in clinical stable phase (no medication change for at least 3 months, PANSS total score < 75, Positive Symptoms Subscale score < 20); 4.with definite cognitive impairment (MCCB total score <= 1.5 SD below the norm or confirmed by baseline assessment); 5.right-handed; 6.able to understand the study content and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Have contraindications to rTMS (such as intracranial metal implants, history of epilepsy, severe heart disease, etc.); 2.suffer from severe physical diseases, neurological diseases, or substance abuse; 3.be pregnant or lactating women; 4.have received electroconvulsive therapy (ECT) or rTMS treatment in the past 6 months; 5.have intellectual disability.

Design outcomes

Primary

MeasureTime frame
Measurement and Treatment Research to Improve Cognition in Schizophrenia (MCCB) Score;Positive and Negative Syndrome Scale(PANSS) Score;Clinical Global Impression Scale (CGI) Score;Calgary Depression Scale for Schizophrenia (CDSS) Score;

Secondary

MeasureTime frame
Insulin-like Growth Factor 2 (IGF-2);

Countries

China

Contacts

Public ContactHu Wei

Jiangxi Mental Health Center

58112103@qq.com+86 791 88176385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026